Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...

New research from the Florida State University Department of Chemistry and Biochemistry shows that a particular type of monoclonal antibody known as NISTmAb retains its structure even if the sugar ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help ...